Moderna, Inc. (NASDAQ: MRNA) Overview: Settlement Impact and Financial Stability

Font: Financial Modeling Prep  • Mar 04, 2026

• Moderna's settlement with Arbutus Biopharma and Genevant Sciences has led to a surge in its stock by over 10%.
• The company plans to appeal for immunity as a government contractor, which could potentially save up to $1.3 billion.
• Moderna expects to end the year with cash reserves between $4.5 billion and $5 billion, bolstering its financial stability for future R&D.

Moderna, Inc. (NASDAQ: MRNA) is a leading biotechnology company renowned for its innovative mRNA technology used in developing vaccines and therapeutics. The company has been in the spotlight for its Covid-19 vaccine, Spikevax, competing with pharmaceutical giants like Pfizer and BioNTech. Recently, Jefferies analyst Andrew Tsai set a price target of $37 for Moderna, while the stock was trading at $49.83, indicating a potential downside of approximately -25.75%.

Moderna's recent settlement with Arbutus Biopharma and Genevant Sciences positively impacted its stock, causing a surge of over 10%. This settlement resolves all global patent litigation related to its Covid vaccines, including Spikevax and mResvia. As part of the agreement, Moderna will pay a one-time fee of $950 million, ensuring no future royalties on these vaccines. This resolution provides certainty for Moderna's vaccine portfolio, potentially enhancing its market position.

Despite the positive impact of the settlement, Moderna plans to appeal to the Federal Circuit court, seeking immunity as a government contractor. If the appeal fails, Moderna may face an additional payment of up to $1.3 billion. However, no accrual has been recorded as the loss is not considered probable. This legal maneuvering highlights the complexities of patent disputes in the pharmaceutical industry.

Following the settlement, Moderna expects to end the year with cash reserves between $4.5 billion and $5 billion. This financial stability is crucial for the company's ongoing research and development efforts, particularly for its next-generation vaccines, mNexspike and mCombriax. The resolution of the patent dispute clears the way for Moderna's vaccine pipeline, providing a more predictable path for future growth.

Currently, Moderna's stock is trading at $49.83, reflecting a decrease of approximately 5.71% for the day. The stock has fluctuated between a low of $48.09 and a high of $51.86 during the trading session. With a market capitalization of approximately $19.47 billion and a trading volume of 8,053,154 shares, Moderna remains a significant player in the biotechnology sector.